Skip to content

Study · Randomized controlled trial · n = 160 · 1996

3 results

A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer.

Debruyne FM, Dijkman GA, Lee DC, Witjes WP, del Moral F, Karthaus HF, van der Mejden AP, Plasman JW, Pull HC, Kums JJ, Idema JG, Hoefakker JW, Heijbroek RP, Kil PJ, Khoe GS

The Journal of urology1 Apr 1996Cited by 26 (Europe PMC)

PMID8632572 (opens in a new tab)DOI10.1016/s0022-5347(01)66264-5 (opens in a new tab)PepBankPUB-08632572
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialActivity measurement

    In advanced prostate cancer, testosterone profiles were similar with 10.8 and 3.6 mg goserelin depots.

    In plain wordsTestosterone profiles were similar with the two goserelin depots in advanced prostate cancer.

    Peptide
    Goserelin
    Outcome
    Direction not reportedSerum testosterone profiles
    Study

    n = 160

    Comparator
    3.6 mg goserelin depot every 4 weeks
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    10.8 mg every 12 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Serum testosterone profiles of the 10.8 and 3.6 mg. goserlin depots were similar with testosterone levels decreasing into the castrate range by day 21 after depot administration.
    2 context sentences
    Summary · context
    To assess the pharmacodynamic equivalence of the new 10.8 mg. goserelin depot with the current 3.6 mg. depot 3 studies were performed in patients with advanced prostate cancer.Materials and methodsIn 2 comparative studies 160 patients were randomized for dosing every 12 weeks using the 10.8…
    Summary · context
    Blood sampling for serum testosterone and evaluation of toxicity was done during the 48-week study period.
  2. 02HumanRandomized controlled trialSafety outcome

    In advanced prostate cancer, the safety profile of 10.8 mg goserelin was comparable to the monthly depot.

    In plain wordsThe two goserelin depots had comparable safety profiles in advanced prostate cancer.

    Peptide
    Goserelin
    Outcome
    Direction not reportedSafety profile
    Study

    n = 160

    Comparator
    3.6 mg goserelin depot every 4 weeks
    Outcome group
    Adverse events · Whole body
    Studied dose
    10.8 mg every 12 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    The safety profile of 10.8 mg. goserelin is comparable to that of the current monthly depot with the main side effects related to androgen deprivation.
    2 context sentences
    Summary · context
    To assess the pharmacodynamic equivalence of the new 10.8 mg. goserelin depot with the current 3.6 mg. depot 3 studies were performed in patients with advanced prostate cancer.Materials and methodsIn 2 comparative studies 160 patients were randomized for dosing every 12 weeks using the 10.8…
    Summary · context
    Blood sampling for serum testosterone and evaluation of toxicity was done during the 48-week study period.
  3. 03HumanNon-randomized trialActivity measurement

    In advanced prostate cancer, both goserelin depots reduced testosterone into the castrate range by day 21.

    In plain wordsBoth goserelin depots reduced testosterone into the castrate range by day 21 in advanced prostate cancer.

    Peptide
    Goserelin
    Outcome
    DecreaseCastrate testosterone
    Study

    n = 160

    Comparator
    Before depot administration
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    10.8 mg every 12 weeks or 3.6 mg every 4 weeks · 48 weeksAs given in this study (human).

    Measurements

    Time to castrate-range testosterone
    ≤ 21 days
    after depot administration

    Source sentences

    Summary
    Serum testosterone profiles of the 10.8 and 3.6 mg. goserlin depots were similar with testosterone levels decreasing into the castrate range by day 21 after depot administration.
    2 context sentences
    Summary · context
    To assess the pharmacodynamic equivalence of the new 10.8 mg. goserelin depot with the current 3.6 mg. depot 3 studies were performed in patients with advanced prostate cancer.Materials and methodsIn 2 comparative studies 160 patients were randomized for dosing every 12 weeks using the 10.8…
    Summary · context
    Blood sampling for serum testosterone and evaluation of toxicity was done during the 48-week study period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.